FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3043370845> ?p ?o ?g. }

• W3043370845 abstract "Yellow Fever (YF) vaccination is suggested to induce a large number of adverse events (AE) and suboptimal responses in patients with autoimmune diseases (AID); however, there have been no studies on 17DD-YF primary vaccination performance in patients with AID. This prospective non-interventional study conducted between March and July, 2017 assessed the safety and immunogenicity of planned 17DD-YF primary vaccination in patients with AID. Adult patients with AID (both sexes) were enrolled, along with healthy controls, at a single hospital (Vitoria, Brazil). Included patients were referred for planned vaccination by a rheumatologist; in remission, or with low disease activity; and had low level immunosuppression or the attending physician advised interruption of immunosuppression for safety reasons. The occurrence of AE, neutralizing antibody kinetics, seropositivity rates, and 17DD-YF viremia were evaluated at various time points (day 0 (D0), D3, D4, D5, D6, D14, and D28). Individuals evaluated (n = 278), including patients with rheumatoid arthritis (RA; 79), spondyloarthritis (SpA; 59), systemic sclerosis (8), systemic lupus erythematosus (SLE; 27), primary Sjogren's syndrome (SS; 54), and healthy controls (HC; 51). Only mild AE were reported. The frequency of local and systemic AE in patients with AID and HC did not differ significantly (8 vs. 10% and 21 vs. 32%; p = 1.00 and 0.18, respectively). Patients with AID presented late seroconversion profiles according to kinetic timelines of the plaque reduction neutralization test (PRNT). PRNT-determined virus titers (copies/mL) [181 (95% confidence interval (CI), 144-228) vs. 440 (95% CI, 291-665), p = 0.004] and seropositivity rate (78 vs. 96%, p = 0.01) were lower in patients with AID after 28 days, particularly those with SpA (73%) and SLE (73%), relative to HC. The YF viremia peak (RNAnemia) was 5-6 days after vaccination in all groups. In conclusion, consistent seroconversion rates were observed in patients with AID and our findings support that planned 17DD-YF primary vaccination is safe and immunogenic in patients with AID." @default.
• W3043370845 created "2020-07-23" @default.
• W3043370845 creator A5000600404 @default.
• W3043370845 creator A5001106269 @default.
• W3043370845 creator A5004221291 @default.
• W3043370845 creator A5008296107 @default.
• W3043370845 creator A5010741865 @default.
• W3043370845 creator A5015884311 @default.
• W3043370845 creator A5017523406 @default.
• W3043370845 creator A5018280562 @default.
• W3043370845 creator A5018625719 @default.
• W3043370845 creator A5019063068 @default.
• W3043370845 creator A5020233707 @default.
• W3043370845 creator A5021498954 @default.
• W3043370845 creator A5022976564 @default.
• W3043370845 creator A5023160213 @default.
• W3043370845 creator A5025754771 @default.
• W3043370845 creator A5028536345 @default.
• W3043370845 creator A5030386265 @default.
• W3043370845 creator A5031100369 @default.
• W3043370845 creator A5042863197 @default.
• W3043370845 creator A5044646917 @default.
• W3043370845 creator A5047554739 @default.
• W3043370845 creator A5050253137 @default.
• W3043370845 creator A5050470455 @default.
• W3043370845 creator A5051264724 @default.
• W3043370845 creator A5052684648 @default.
• W3043370845 creator A5055017119 @default.
• W3043370845 creator A5055181669 @default.
• W3043370845 creator A5056633426 @default.
• W3043370845 creator A5057319230 @default.
• W3043370845 creator A5057340518 @default.
• W3043370845 creator A5059003875 @default.
• W3043370845 creator A5060243147 @default.
• W3043370845 creator A5060422799 @default.
• W3043370845 creator A5061237002 @default.
• W3043370845 creator A5061761843 @default.
• W3043370845 creator A5068689705 @default.
• W3043370845 creator A5069793092 @default.
• W3043370845 creator A5073688573 @default.
• W3043370845 creator A5073735715 @default.
• W3043370845 creator A5073981258 @default.
• W3043370845 creator A5074008709 @default.
• W3043370845 creator A5074885902 @default.
• W3043370845 creator A5075854813 @default.
• W3043370845 creator A5079783990 @default.
• W3043370845 creator A5084234178 @default.
• W3043370845 creator A5087434199 @default.
• W3043370845 creator A5089031385 @default.
• W3043370845 creator A5091320118 @default.
• W3043370845 date "2020-07-17" @default.
• W3043370845 modified "2023-10-16" @default.
• W3043370845 title "Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study" @default.
• W3043370845 cites W1520457655 @default.
• W3043370845 cites W1574276508 @default.
• W3043370845 cites W1861582559 @default.
• W3043370845 cites W1965938470 @default.
• W3043370845 cites W1967538787 @default.
• W3043370845 cites W2003760082 @default.
• W3043370845 cites W2005333995 @default.
• W3043370845 cites W2016480047 @default.
• W3043370845 cites W2029074520 @default.
• W3043370845 cites W2034373993 @default.
• W3043370845 cites W2056738439 @default.
• W3043370845 cites W2062184388 @default.
• W3043370845 cites W2095406037 @default.
• W3043370845 cites W2101453675 @default.
• W3043370845 cites W2103733826 @default.
• W3043370845 cites W2109172918 @default.
• W3043370845 cites W2111553271 @default.
• W3043370845 cites W2128952811 @default.
• W3043370845 cites W2141928565 @default.
• W3043370845 cites W2142239745 @default.
• W3043370845 cites W2143835145 @default.
• W3043370845 cites W2149763923 @default.
• W3043370845 cites W2155539357 @default.
• W3043370845 cites W2159860161 @default.
• W3043370845 cites W2171715136 @default.
• W3043370845 cites W2256828485 @default.
• W3043370845 cites W2299402461 @default.
• W3043370845 cites W2311590422 @default.
• W3043370845 cites W2412755673 @default.
• W3043370845 cites W2508060872 @default.
• W3043370845 cites W2529373723 @default.
• W3043370845 cites W2540091234 @default.
• W3043370845 cites W2586027079 @default.
• W3043370845 cites W2594592790 @default.
• W3043370845 cites W2603973134 @default.
• W3043370845 cites W2738241381 @default.
• W3043370845 cites W2942846347 @default.
• W3043370845 cites W2944250071 @default.
• W3043370845 cites W4255504044 @default.
• W3043370845 doi "https://doi.org/10.3389/fimmu.2020.01382" @default.
• W3043370845 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7379374" @default.
• W3043370845 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32765496" @default.
• W3043370845 hasPublicationYear "2020" @default.
• W3043370845 type Work @default.
• W3043370845 sameAs 3043370845 @default.
• W3043370845 citedByCount "12" @default.
• W3043370845 countsByYear W30433708452020 @default.

• next